AzTrials
AzTrials

Subsegmental Pulmonary EmbolismNCT07575503

Diagnostic Value of Photon-Counting CT in Subsegmental Pulmonary Embolism

An observational study of Subsegmental Pulmonary Embolism and Photon-Counting Computed Tomography, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Pulmonary embolism (PE) is a serious and potentially life-threatening condition caused by blood clots in the lungs. A particular type, subsegmental pulmonary embolism (SSPE), involves very small branches of the pulmonary arteries. Read more about this study

Who is it for?
Ages 18 years and older
How many people
696 participants
Where
1 siteChina
Study dates
1 Jan 2026to Jan 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adults (≥18 years) presenting with clinical symptoms and signs suggestive of acute pulmonary embolism will be enrolled. Eligible patients are those with a simplified revised Geneva score ≥3 and abnormal findings on electrocardiogram, echocardiography, or pulse oximetry, which support the suspicion of pulmonary embolism. Patients will be prospectively recruited from the emergency department and inpatient wards of the Second Affiliated Hospital, Zhejiang University School of Medicine. The study population is representative of patients with suspected acute pulmonary embolism who require CT pulmonary angiography for diagnostic confirmation.

Who may be able to join

  • Age ≥ 18 years
  • Clinical manifestations supporting the diagnosis of acute pulmonary embolism, including:
  • Acute onset or progressive dyspnea Unexplained hypoxemia Chest pain Hemoptysis Syncope or presyncope Combined with abnormal findings on electrocardiogram, echocardiography, or pulse oximetry
  • Revised simplified Geneva score ≥ 3
  • Written informed consent obtained from the patient or the patient's legally authorized representative

Who cannot join

  • Patients requiring prophylactic or therapeutic doses of anticoagulant medication for reasons other than venous thromboembolism (VTE).
  • Life expectancy less than three months.
  • Patients unable to undergo CT scanning due to severe condition or hemodynamic instability.
  • History of allergy to contrast media, renal insufficiency (creatinine clearance < 30 mL/min), or ongoing long-term dialysis.
  • Pregnancy.
  • Refusal to provide informed consent or inability to complete follow-up for any reason.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

China1 site, 1 recruiting
  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310009

    min Yan, doctor, +86 13757118632, zryanmin@zju.edu.cn

    Recruiting

Other trials in China

About this study

Official title: Application of Photon-Counting Computed Tomography in the Diagnosis of Subsegmental Pulmonary Embolism

Pulmonary embolism (PE) is a serious and potentially life-threatening condition caused by blood clots in the lungs. A particular type, subsegmental pulmonary embolism (SSPE), involves very small branches of the pulmonary arteries. Although these clots occur in smaller vessels, their risk of recurrence and complications may be similar to larger clots.

Conventional CT pulmonary angiography (CTPA) is the standard imaging test for suspected PE, but image quality can sometimes be limited by motion artifacts, poor contrast filling, or body habitus, making the detection of SSPE challenging.

Read more

Photon-counting computed tomography (PCCT) is a new CT technology that provides higher image resolution, lower radiation dose, and improved visualization of small blood vessels. Early studies suggest PCCT may reduce motion artifacts and increase the accuracy of detecting SSPE compared with conventional CT.

This prospective cohort study will compare PCCT with dual-source CT in patients with suspected acute PE. The study aims to determine whether PCCT improves the detection rate and image quality for SSPE, and whether it can provide more reliable diagnostic information to guide clinical care.

Read the detailed description

Pulmonary embolism (PE) is a leading cause of morbidity and mortality worldwide. Subsegmental pulmonary embolism (SSPE), defined as thrombi confined to subsegmental pulmonary arteries, may account for up to 20% of acute PE cases detected by multidetector CT. While distal in location, SSPE carries a risk of recurrent venous thromboembolism and mortality that is comparable to more proximal PE, suggesting that SSPE is not a benign entity. Accurate diagnosis is therefore clinically important, but remains challenging due to motion artifacts, poor contrast opacification, and the large number of small subsegmental vessels that must be evaluated.

Photon-counting computed tomography (PCCT) is a recently developed imaging technology that offers significant improvements over conventional energy-integrating detector CT (EID-CT). PCCT provides higher spatial resolution, direct spectral information, and the ability to generate virtual monoenergetic images and iodine maps in a single acquisition, while reducing radiation dose. Preliminary studies indicate that PCCT can minimize motion artifacts, improve image quality, and enhance visualization of small pulmonary arteries, potentially increasing the detection of SSPE.

This prospective observational cohort study will compare the diagnostic performance of PCCT with dual-source CT in patients with suspected acute PE. The primary outcome is the detection rate of SSPE. Secondary outcomes include image quality scores, radiation dose, and the added diagnostic value of PCCT in patients with negative findings on dual-source CT. By systematically evaluating image quality, detection yield, and radiation exposure, this study seeks to establish the potential role of PCCT as a superior diagnostic tool for SSPE in real-world clinical practice.

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07575503
Study groupRoleWhat they receive
Group 1Title: Conventional CT groupDescription: Patients with suspected pulmonary embolism who undergo dual-source or energy-integrating detector CT pulmonary angiography (EID-CTPA).
Group 2 Title: Photon-counting CT groupDescription: Patients with suspected pulmonary embolism who undergo photon-counting computed tomography (PCCT) for diagnosis.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Detection rate of subsegmental pulmonary embolism (SSPE) using photon-counting CT versus dual-energy CT

    The proportion of patients with suspected acute pulmonary embolism in whom SSPE is detected on photon-counting CT compared with dual-energy CT. All scans will be independently assessed by two blinded radiologists to determine diagnostic yield.

    Measured: perioperative period

Secondary outcomes (3)
  1. Objective image quality scores for SSPE diagnosis

    ignal-to-Noise Ratio (SNR) and Contrast-to-Noise Ratio (CNR) will be calculated based on CT attenuation and image noise measured in standardized Regions of Interest (ROIs) within pulmonary vessels, the aorta, and paraspinal muscles. Higher SNR and CNR values indicate better objective image quality.

    Measured: perioperative period

  2. Subjective image quality scores for SSPE diagnosis

    Radiologists will qualitatively assess image noise and motion artifacts using a 5-point Likert scale (1 = Unacceptable, 5 = Excellent). The average score of the readers will be used, with higher scores indicating better subjective image quality

    Measured: perioperative period

  3. Incidence of Venous Thromboembolism (VTE)

    Occurrence of symptomatic VTE, defined as Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), confirmed by objective imaging upon clinical suspicion

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 May 2026
  2. Study start1 Jan 2026
  3. Primary completionSep 2026 (estimated)
  4. Study completionJan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
696 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07575503
Sponsor's protocol ID
2025-1248
Status last verified
Sep 2025
First submitted
17 Nov 2025
Last updated
8 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Subsegmental Pulmonary Embolism and Photon-Counting Computed Tomography, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Detection rate of subsegmental pulmonary embolism (SSPE) using photon-counting CT versus dual-energy CT (time frame: perioperative period). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in